Interested In A Potential #Oncology Breakthrough? Phase IIb Results For Our Fast-Tracked Drug Candidate Onilcamotide Are Imminent!
RhoVac AB announces Database Lock in its clinical phase IIb trial of onilcamotide.
#prostatecancer
rhovac.com/cision/1A93E73D52…
We are proud to be featured in @TheTelegraph__ newspaper in a comprehensive article that reviews a range of therapies for #prostatecancer. Our #cancervaccine stands out in that it is intended to protect treated prostate cancer patients from metastases.
telegraph.co.uk/health-fitne…
RhoVac AB retweeted
Lundabolaget @RhovacAB tar i 25 miljoner kronor i en nyemission. Företag utvecklar ett vaccin mot prostatacancer som nu prövas i kliniska studier.
lifesciencesweden.se/article…
Today is the last day to take advantage of our recent share rights issue!
#cancervaccine #metastasis
2
Watch @BioStock_SWE's discussion around the investment case in RhoVac and learn more about the market potential for our cancer vaccine Onilcamotide for the treatment of #prostatecancer.
youtu.be/q0Q7WGZzVnA
2
RhoVac AB retweeted
Först ut i programmet är @RhovacAB vd Anders Månsson, live cirka 12.02 youtu.be/xPQA3EB7_Bk
Tune in to @direktse's Trading Direkt Healthcare YouTube channel and hear more about our clinical phase IIb study for our candidate RV001, and our mission to prevent and treat cancer progression after surgery or radiation to the primary tumour.
youtube.com/watch?v=xPQA3EB7…
1
Missed our CEO Anders Månsson's IR presentation last night at @aktiespararna's Aktiedagen Stockholm event? His talk is now available on-demand. Learn more about Rhovac and our work to prevent cancer recurrence and progression after primary tumour therapy.
youtube.com/watch?v=0osUZCj8…
Our CEO Anders Månsson will be speaking at the Stora Aktiedagarna event on March 15th, at 19:00. Learn more about RhoVac's latest company updates and exciting upcoming milestones.
Visit the @aktiespararna website to learn more about registration.
aktiespararna.se/aktiviteter…
Get new insight and learn about RhoVac's exciting upcoming milestones via the latest analysis by @aktiespararna in their #Analysguiden.
Note, the Analysguiden is available in Swedish.
#metastasis #cancer #cancervaccines
aktiespararna.se/analysguide…
We are happy to report that Edison have updated their guidance on RhoVac, featuring a further increase on our recommended share price to 89.5 SEK per share (previously 84.9 SEK/share).
edisongroup.com/publication/…
1
Our year-end report for the financial year 2021 is now published.
Read the report on our website (in Swedish) and learn how RhoVac is positioned for our Phase IIb study finalisation.
rhovac.se/cision/31DC305CEA2…
#cancer #metastasis #rhovac
1
We are pleased to announce today that the Board of Directors intends to execute a preferential rights issue of a convertible loan of approx. 25 M SEK in March/April 2022. Read more at our website.
rhovac.com/cision/37CA38179B…
1
RhoVac AB retweeted
Complement: RhoVac plans for a fully guaranteed convertible loan rights issue, to finance activities following a successful clinical phase IIb study outcome dlvr.it/SJfFjr
RhoVac AB retweeted
Komplettering: RhoVac planerar för en fullt garanterad företrädesemission av konvertibler, för att finansiera aktiviteter som följer av ett positivt resultat i den kliniska fas IIb-studien dlvr.it/SJfFzh
RhoVac AB retweeted
RhoVacs vd kommenterar konvertibelemission #BioStockSwe #LifeScience #RhoVac biostock.se/2022/02/biostock…












